Alzheimer's treatment

In an unexpected reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug Administration approval for aducanumab, an experimental treatment for early Alzheimer's disease, Biogen and its Japanese partner Eisai announced on Tuesday.

Phase 3 clinical studies of aducanumab were discontinued in March. The trials were halted because results of a futility analysis found they were unlikely to meet their primary goals at completion.
On Tuesday, Biogen announced that a new analysis, which included more patients, showed a significant reduction in clinical decline in one trial. Results for some patients in another study support those findings, as well.


The data showed that patients who received aducanumab experienced significant benefits on measures of cognition and function, including memory, orientation and language, according to Biogen... https://edition.cnn.com/2019/10/22/health/biogen-alzheimers-drug-fda/index.html

Popular posts from this blog

Third degree torture used on Maruti workers: Rights body

Haruki Murakami: On seeing the 100% perfect girl one beautiful April morning

The Almond Trees by Albert Camus (1940)

Rudyard Kipling: critical essay by George Orwell (1942)

Satyagraha - An answer to modern nihilism

Three Versions of Judas: Jorge Luis Borges

Goodbye Sadiq al-Azm, lone Syrian Marxist against the Assad regime